India to Turkey: Fluticasone Export Trade Route

The India to Turkey Fluticasone corridor is one of India's established pharmaceutical export routes, with 103 shipments documented worth a combined $8.5M USD. The route is dominated by CIPLA LIMITED, which alone accounts for roughly 64% of all export value, reflecting the consolidated nature of India's fluticasone manufacturing sector.

Across 10 active suppliers, the average shipment value stands at $82.5K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 70% of all shipments, consistent with fluticasone's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 19 days port-to-port. The route has recorded an annual growth rate of 18.4%, placing it at rank #7 among India's top fluticasone export destinations globally.

On the import side, key buyers of Indian fluticasone in Turkey include PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR, VIATRIS LACLAR LTD TI D.C., PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR and 9 others. PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR is the single largest importer with 81 shipments valued at $7.6M USD.

India's fluticasone exports to Turkey are driven primarily by a handful of large-scale manufacturers. CIPLA LIMITED with 68 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 10 active exporters signals a competitive but concentrated market — buyers in Turkey benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — CIPLA LIMITED, MEDISPRAY LABORATORIES PRIVATE LIMITED, CIPLA LIMITED — together account for 99% of total trade value on this route. The average shipment value of $82.5K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as flohale 250 hfa inhaler fluticasone pro and seroflo 125 hfa inhaler (with dose indicator) (salmeterol xinafoate 25mcg+fluticasone propionate 125mcg ) (1 x 120 md), suggesting that buyers in Turkey tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR is the largest importer with 81 shipments worth $7.6M USD — representing 90% of all fluticasone imports from India on this route. A total of 12 buyers are active on this corridor.